Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer

Next Previous
X
Search
Trial Profile

Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alectinib (Primary) ; Crizotinib
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ALESIA
  • Sponsors Roche

    • Most Recent Events

    • 12 Sep 2023 Results comparing efficacy and safety of lorlatinib vs alectinib and brigatinib using matching adjusted indirect comparisons using patient level data from lorlatinib RCT (CROWN) to match the aggregate baseline characteristics of the comparator RCTs (alectinib: ALEX, ALESIA; brigatinib: ALTA-1L), presented at the 24th World Conference on Lung Cancer.
    • 14 Apr 2023 Planned End Date changed from 6 Dec 2019 to 31 Mar 2026.
    • 17 Jun 2021 Results of meta analysis from ALTA-1L, ALEX, CROWN, ALESIA and J-ALEX; comparing the relative efficacy of orlatinib, alectinib and brigatinib for patients with ALK inhibitor-naive or previously untreated ALK-positive advanced NSCLC, published in the Journal of Chemotherapy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top